Brookline, United States
Ibex Medical Analytics is at the forefront of revolutionizing the field of pathology through its pioneering AI-based cancer diagnostics. Founded in 2016, the company addresses the increasing challenges faced by pathologists, who struggle with overwhelming workloads, higher cancer prevalence, and the growing complexity of diagnostics due to personalized medicine.
Utilizing cutting-edge artificial intelligence, Ibex has developed clinical-grade algorithms and digital workflows that match the accuracy of human pathologists. Their platform, which has proven effective in clinical studies, enhances the quality and efficiency of cancer diagnosis while reducing diagnostic errors and increasing productivity.
Headquartered in the United States, Ibex has established itself as the first-ever AI-powered cancer diagnostics platform widely used in routine clinical practices globally. In September 2023, the company secured a $55.00M Series C investment from notable investors, including Octopus Ventures, 83North, aMoon, Dell Technologies Capital, Planven Investments, and Sienna Investment Managers, solidifying its position as a leader in AI-driven healthcare innovation.
The Pathology Network